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Introduction
Age-related macular degeneration (AMD) is a leading cause of 
irreversible vision loss worldwide and has a profound impact on 
the quality of life of many individuals. It is classified into 2 
main types: nonexudative (also known as “dry” or “non-neovas-
cular”) and exudative (“wet” or “neovascular”). Dry AMD is 
characterized by drusen, retinal pigment epithelium (RPE) 
changes, and, in advanced forms, geographic atrophy—conflu-
ent areas of regressed drusen and RPE atrophy. Wet AMD is 
characterized by the development of neovascularization under 
the retina or RPE that results in leakage of fluid and hemor-
rhage in the intraretinal, subretinal, or sub-RPE space. Severe 
vision loss occurs primarily due to 2 processes: geographic atro-
phy in advanced nonexudative AMD and choroidal neovascu-
larization (CNV) in exudative AMD culminating in fibrosis.
Advancements in imaging over the past 15 years have revo-
lutionized the diagnosis and treatment of AMD. Imaging is 
especially critical at 2 junctures in the course of the disease: (1) 
monitoring for the development of CNV and leakage (signify-
ing the progression to exudative AMD) and (2) monitoring the 
response to anti–vascular endothelial growth factor (anti-
VEGF) therapy in exudative disease. Since 1961, the criterion 
standard for retinal vascular imaging has been fluorescein angi-
ography (FA).1 Traditional FA uses a fluorescent dye to visual-
ize the retinal and choroidal vasculature. Clinically, FA images 
are essential in assessing the presence and extent of abnormal 
vascular permeability and provide the clinician with vital cues 
regarding the transformation from nonexudative to exudative 
AMD.2 Its greatest utility is in showing dynamic changes in 
fluorescent patterns, such as leakage, staining, and pooling, as 
well as dye transit time to the eye. However, FA provides only 
a limited 2-dimensional (2D) depth resolution of the retinal 
and choroidal vasculature and poorly visualizes vessels that may 
be obscured by fluid, hemorrhage, pigment, RPE detachments, 
fibrosis, or other areas of hyperfluorescence.2,3 Neovascular 
patterns under the RPE are difficult to evaluate as well. 
Therefore, given that changes to the retinal and choroidal vas-
culature are inferred as opposed to directly visualized, FA 
images require an experienced clinician to interpret. In contrast 
to FA, indocyanine green angiography (ICGA) uses a dye that 
does not usually leak from neovascular membranes, so it can be 
used to provide a more detailed image of the choroid and in 
particular neovascular membranes beneath the RPE, as well as 
in the AMD variants idiopathic polypoidal choroidal vascu-
lopathy (IPCV) and retinal angiomatous proliferation (RAP). 
Both procedures involve invasive injections of dyes that can 
cause adverse effects ranging from nausea and vomiting to ana-
phylactic reactions and very rarely death.
In the past decade, optical coherence tomography (OCT) 
has established itself as an essential imaging modality in the 
diagnosis and management of AMD.4 Optical coherence 
tomography is currently the primary method to monitor for 
structural changes, such as neovascular membranes, fibrosis, 
intraretinal and subretinal fluid, and pigment epithelial detach-
ments. Exudation manifests as intraretinal and subretinal fluid 
and retinal thickening on OCT. Sequential OCT imaging ena-
bles clinicians to monitor response to anti-VEGF therapy in 
exudative AMD by following intraretinal and subretinal fluid 
and retinal thickening as well as pigment epithelial detach-
ments. Optical coherence tomography is easier and faster to 
acquire than FA, does not require invasive injections, and pro-
vides cross-sectional and en face images of retinal and choroi-
dal features. However, it does not provide detailed visualization 
of the neovascular membrane itself, and oftentimes, it can be 
difficult to distinguish CNV from subretinal fibrosis, fibrotic 
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pigment epithelial detachments, hemorrhage, drusenoid mate-
rial, or adjacent retinal tissue, RPE, and the Bruch membrane 
due to similar reflectivities.5
Optical Coherence Tomographic Angiography
In recent years, a new imaging modality known as optical 
coherence tomographic angiography (OCTA) has been devel-
oped to simultaneously obtain structural images of the retina as 
well as assess blood flow within the retinal and choroidal vas-
culature without the use of intravenous agents.
Optical coherence tomographic angiography provides vas-
cular imaging via motion contrast processing of decorrelation 
signals. Decorrelation signals are generated by variable signal 
intensities and amplitudes obtained from sequential B scans in 
a single area of the posterior segment.6 After bulk axial move-
ment has been eliminated via software, the remaining differ-
ences in signals and amplitudes of sequential B scans are 
thought to represent the flow of erythrocytes within vascula-
ture. Finally, signal differences are processed by various algo-
rithms to create a functional vascular map of the retina and 
choroid.
Thus far, 3 broad categories of imaging algorithms have 
been used: (1) phase based, (2) amplitude based, and (3) com-
plex algorithm based (combination of phase based and ampli-
tude based).6 The most common algorithm in use with the 
current spectral domain OCTA (SD-OCTA) machine is split-
spectrum amplitude-decorrelation angiography (SSADA). 
The SSADA algorithm, developed by Huang and colleagues,6 
optimizes the signal-to-noise ratio of flow detection to provide 
a higher quality image. In SSADA, bulk motion noise is sig-
nificantly reduced in the axial direction, whereas flow signal 
remains preserved in the transverse direction, resulting in 
higher resolution OCTA images.1 Using the SSADA OCTA 
algorithm, Huang and Bailey et al were able to demonstrate the 
presence of distinct superficial and deep capillary networks 
within the retina, as well as the absence of vascular flow in the 
foveal avascular zone, indicating minimal noise artifact.6–8
Given that OCTA technology is inherently OCT based, 
OCTA images are depth resolved on a micrometer scale.9 
Optical coherence tomographic angiograms can further be 
manually or automatically segmented with preprogrammed 
software to highlight individual layers of the retina, choriocap-
illaris, and choroid (Figure 1). The user can either analyze en 
face images extending from the inner limiting membrane to 
choroid or use automated views to locate a vascular or struc-
tural lesion within the retina.2
Optical coherence tomographic angiography requires higher 
imaging speeds than most existing clinical OCT models. The 
most commonly used OCTA system is the prototype RTVue 
XR Avanti SD-OCT with AngioVue software (Optovue Inc., 
Fremont, CA, USA). This system uses an 840-nm wavelength 
light source and obtains 304 × 304 A scans at a rate of 70 000 
scans per second. The software can obtain scans ranging in size 
from 2 × 2 mm to 8 × 8 mm.10
Given that retinal capillary vessels have an average diameter 
of approximately 6 to 8 µm, it is important to assess the image 
Figure 1. Optical coherence tomographic (OCT) angiography in a healthy right eye of a 74-year-old man: (A) spectral domain OCT B scan through the 
fovea (corresponding to the white dotted line in B), (B) en face structural OCT, (C) 3 × 3 mm spectral domain OCT angiogram of the choriocapillaris 
centered on the fovea (acquired using RTVue XR Avanti; Optovue Inc., Fremont, CA, USA) with split-spectrum amplitude-decorrelation angiography 
software, (D) OCT angiogram of the outer retina showing absence of blood flow, (E) OCT angiogram of the deep capillary plexus, and (F) OCT angiogram 
of the superficial capillary plexus.
Ma et al 3
resolution of OCTA systems.9 Axial resolution of OCT angio-
grams is determined by the bandwidth of the accompanying 
light source, and increasing bandwidth translates to improved 
image resolution. Currently, the axial resolution for an 800-nm 
system is approximately 7 to 10 µm, and the resolution for a 
1200-nm system is approximately 10 to 20 µm. Therefore, with 
the 840-nm light source in the current RTVue system, image 
resolution is within an acceptable range of 7 to 10 µm.
To preserve adequate image resolution, the OCTA systems 
must forgo a larger scan size. The largest scan size obtainable 
with the available technology is 12 × 12 mm. However, at this 
size, there is a clinically significant decline in image resolu-
tion. Therefore, the most commonly used scan size is 3 × 3 
mm with the current SD-OCTA technology.2 When com-
pared with FA and indocyanine green (ICG) images, this 
smaller scan size may represent a potential limitation of the 
OCTA technology.
In an effort to improve the axial and lateral resolution of 
images, and thereby to increase the scan size, a new prototype 
has been developed by the Massachusetts Institute of 
Technology known as swept source OCT (SS-OCT). In addi-
tion to using a vertical cavity surface-emitting laser, a 1060-nm 
wavelength light source, the SS-OCTA system also has a 
higher imaging speed. The SS-OCT obtains 500 × 500 A 
scans at a rate of 400 000 scans per second in approximately 3.8 
seconds.10 Although the standard SD-OCTA system allows 
posterior segment imaging just greater than 1 mm in depth, the 
SS-OCTA system has an imaging range of approximately 2.44 
mm.11,12 As a result, this system allows for improved view of 
the choroidal vasculature in addition to improved image qual-
ity. Yet, the most commonly used scan sizes are 3 × 3 mm or 6 
× 6 mm. Therefore, even with the current advances in technol-
ogy, the inability to visualize larger areas of the retina and cho-
roid may still pose a disadvantage for clinical use.
Another significant drawback to the OCTA system is the 
potential for various forms of artifact. Bulk motion artifact, due 
to poor fixation or an uncooperative patient, results in horizon-
tal or vertical white lines on imaging.2 Because signals from 
consecutive B scans are used to map retinal and choroidal vas-
culature, any movement that exceeds the maximum detectable 
velocity, determined by time interval between sequential B 
scans, has the ability to create motion artifact.13 Another type 
of artifact is referred to as a “projection” artifact in which more 
superficial retinal vasculature is projected onto deeper layers of 
the retina and choroid, resulting in the appearance of “ghost 
vessels.”2 Furthermore, projection artifacts of the choriocapil-
laris and choroid can also result from simple attenuation and 
scattering from the RPE layer.
Although faster scanning speeds may overcome the motion 
artifact, it is possible that at these higher scanning speeds, 
OCTA may not be able to adequately capture slow flow states, 
such as those seen in microaneurysms or fibrotic CNV. The 
slowest detectable flow rate is set by the time interval between 
2 consecutive B scans. As a result, OCTA technology requires 
a significant trade-off between overall acquisition time, elimi-
nation of bulk motion, and comprehensive vascular imaging.
Overall, the current OCTA technology is promising and 
certain limitations encountered in the current system are being 
actively addressed through small research studies. In general, 
OCTA provides vascular imaging in different layers of the 
retina and choroid that is not possible with current FA/ICG 
images. The elimination of exogenous dye for image acquisi-
tion and the faster image collection times are significant bene-
fits for clinical practice. Yet, despite these advantages, one must 
remember that as a new technology, OCTA is limited in clini-
cal use by the lack of large studies demonstrating the accuracy 
of current segmentation technology and the overall reproduci-
bility of data.1,14 Furthermore, OCTA can only provide infor-
mation regarding vascular flow at a single time point and 
cannot demonstrate dynamic vascular leakage, as is possible 
with FA and ICG.
OCTA in Nonexudative AMD
More than 80% of patients with AMD have the nonexudative 
form, which is characterized by the presence of drusen, RPE 
abnormalities, and geographic atrophy (Figure 2). Because 
patients with mild nonexudative AMD can maintain reasona-
bly good visual acuity, there is much interest in improving the 
early detection of CNV before it distorts the retinal architec-
ture and leads to vision loss.
The presence of CNV in 1 eye is a known risk factor for 
progression to wet AMD in the fellow eye. Huang and Bailey 
et al have used SD-OCTA (RTVue XR Avanti AngioVue) to 
screen eyes with nonexudative AMD at risk of developing exu-
dative AMD based on having exudative AMD in the fellow 
eye.15 Study participants had exudative AMD in one eye and 
nonexudative AMD in the fellow eye based on the presence of 
drusen and retinal pigment epithelial changes. Of the 32 eyes 
with nonexudative AMD, 2 were found to have a vascular 
membrane on OCTA that did not show leakage on FA nor the 
presence of intraretinal or subretinal fluid on OCT. In both 
patients, the vascular membrane appeared in the sub-RPE 
space on en face OCT angiograms, consistent with type I 
CNV. In one of the eyes, the CNV was located within a pig-
ment epithelial detachment. Although one of the patients was 
lost to follow-up, the other was monitored for 8 months with-
out any treatment. On follow-up angiograms, there was a 20% 
increase in CNV flow area but no evidence of fluid or leakage 
on OCT and FA.
In a similar study, Rosenfeld and colleagues16 followed 11 
patients with asymptomatic intermediate, nonexudative AMD 
(defined as the presence of many medium-sized drusen [63-
125 µm] or at least 1 large drusen [>125 µm] or noncentral 
geographic atrophy) in one eye and type I neovascular AMD in 
the fellow eye using a modified Zeiss 1050-nm SS-OCT pro-
totype. In 3 of the 11 eyes, ICGA showed a central macular 
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plaque. Fluorescein angiography of these 3 eyes showed areas 
of early focal hyperfluorescence with late staining and no leak-
age, consistent with nonexudative AMD. Standard OCT B 
scans through these areas showed elevations of the RPE nor-
mally consistent with typical drusen without evidence of fluid. 
However, on SS-OCTA, there was evidence of blood flow 
within the presumed drusen. These lesions could be classified 
as type I CNV based on the en face images and corresponded 
with the location of the plaques seen on ICG. Others have 
previously described subclinical CNV lesions that are detected 
as staining plaques on ICGA and give the appearance of drusen 
but are not associated with leakage on FA or intraretinal or 
subretinal fluid on OCT.17 Eyes with these so-called nonexu-
dative CNV lesions have no clinical signs of exudative AMD, 
and it remains unclear whether their presence represents a 
precursor to exudative AMD. Gass18 has proposed that early 
CNV networks have minimal or no exudation due to low flow 
and that exudation results from increases in blood flow with 
time. Additional longitudinal studies of nonexudative CNV are 
necessary to discern the natural history of these vascular lesions.
Mastropasqua and colleagues19 used SD-OCTA (RTVue 
XR Avanti AngioVue) to compare superficial and deep retinal 
vascular plexus densities and choroidal thickness in patients 
with early (defined as having medium drusen [63-125 µm] but 
without pigmentary abnormalities) and intermediate AMD as 
well as normal eyes. Vessel density was quantified as the per-
centage of a 3 mm × 3 mm region centered on the foveal avas-
cular zone occupied by vessels. They found a significant 
reduction in choroidal thickness and superficial and deep reti-
nal vessel densities between patients with AMD and healthy 
Figure 2. Optical coherence tomographic (OCT) angiography in nonexudative age-related macular degeneration in the right eye of an 80-year-old 
woman, with exudative AMD in the fellow eye (not shown). (A) Color fundus photograph showing numerous drusen, enlarged to approximate area of 
following OCT angiograms; (B) SD-OCT B scan through a drusen (corresponding to the white dotted line in B); (C) en face structural OCT showing dark 
areas corresponding to drusen; (D) 3 × 3 mm spectral domain optical coherence tomographic (SD-OCT) angiogram of the choriocapillaris showing 
shadowing artifact and/or flow impairment in areas under the drusen; (E) OCT angiogram of the outer retina showing absence of choroidal 
neovascularization; (F) OCT angiogram of the deep capillary plexus appears uninvolved; and (G) OCT angiogram of the superficial capillary plexus 
appears uninvolved.
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controls but no significant difference in these measurements 
between early AMD and intermediate AMD patients.
OCTA in Exudative AMD
Exudative AMD accounts for about 10% to 15% of AMD 
cases but is responsible for 90% of cases with vision loss.20,21 
The appearance of leakage and fluid from CNV defines the 
progression from nonexudative to exudative AMD. With the 
recent development of effective anti-VEGF agents for the 
treatment of exudative AMD, there is a critical emphasis on 
correctly classifying the stage of AMD and type of CNV 
present.22
CNV has been classified into 3 different types: type I CNV, 
type II CNV, and type III CNV. In type 1 CNV, vessels arising 
from the choroid penetrate the Bruch membrane and invade 
the subretinal pigment epithelial space (Figure 3). In type II 
CNV, vessels also originate from the choroid but infiltrate 
between the RPE and retina. Type III CNV, also known as 
RAP, is thought to arise from downward proliferation of the 
deep plexus layer of retinal vessels to the RPE (Figure 4). There 
has been growing interest in studying the characteristics of 
CNV lesions in neovascular AMD using OCTA.
Huang and Bailey et al imaged treatment-naive exudative 
AMD patients using SS-OCTA (prototype with 1050-nm 
laser) and segmented 3-dimensional (3D) angiograms into 3 
slabs: inner retinal layer (containing the internal limiting mem-
brane to the outer plexiform layer), outer retinal layer (contain-
ing the outer plexiform layer to the Bruch membrane), and 
choroidal layer (below the Bruch membrane).23 Optical coher-
ence tomographic angiograms of patients with exudative AMD 
show structural details of CNV lesions with great depth resolu-
tion, and viewing them on cross section identifies their exact 
position, enabling classification as type I, type II, or type III 
CNV. In their limited sample of 5 patients with exudative 
AMD, they found that larger CNV networks had higher blood 
flow than smaller lesions and that type II CNV had higher 
blood flow than type I CNV or combined type CNV. In 1 eye 
with subretinal hemorrhage overlying the CNV, the hemor-
rhage did not obscure the view of the CNV. In all eyes with wet 
AMD, there were prominent deep choroidal vessels and loss of 
choriocapillaris. In addition, in some of these eyes, OCTA 
images showed diminished perfusion of the choriocapillaris 
and deeper choroid under the CNV. As they propose, this may 
be evidence of a role of choroidal circulation abnormalities and 
outer retinal ischemia in the pathogenesis of CNV and AMD, 
as a growing body of literature has hypothesized.24–26
Sarraf and colleagues27 described the morphologic charac-
teristics of type I CNV lesions on OCTA (RTVue XR Avanti 
AngioVue). In their study of 33 eyes with AMD, all had previ-
ously been treated with anti-VEGF (mean number of injec-
tions received was 15.3). They described 2 distinct appearances 
of type I membranes: a “medusa” form (about 55% of the 
lesions) with vessels radiating in all directions from a large 
main feeder vessel and a “seafan” form (about 25% of lesions) 
where most of the smaller vessels radiated from one side of a 
large feeder vessel. The remaining vascular membranes lacked 
distinct smaller vessels. Lesions were quantified by measuring 
area, width of the largest caliber vessel, and density of vessels. 
Overall, there was no correlation between the morphologic 
pattern of the lesions and the presence of RPE detachment, the 
presence of RPE atrophy, or the number of anti-VEGF injec-
tions received. Notably, there was also no significant change in 
the area and vessel density of type I CNV lesions at baseline 
and at follow-up imaging after further anti-VEGF therapy, 
although qualitatively there appeared to be attenuation of some 
of the finer vessels in some of the eyes after anti-VEGF injec-
tions. The authors posit that the lack of change in morphology 
after anti-VEGF injections likely reflects the chronicity of the 
lesions. Like Huang and colleagues,23 they also found that in 
Figure 3. Type I choroidal neovascularization (CNV) in exudative 
age-related macular degeneration in the right eye of a 67-year-old woman, 
status post 9 ranibizumab injections and 13 aflibercept injections. (A) 3 × 3 
mm spectral domain optical coherence tomographic (SD-OCT) angiogram 
of the choriocapillaris showing a neovascular membrane centrally; (B) en 
face structural optical coherence tomography (OCT) of the same area 
showing patchy hyperreflectivity, with hyporeflectivity corresponding to 
subretinal fluid; (C) OCT B scan through area of CNV and subretinal fluid 
(corresponding to the white dotted line in B). Fluorescein angiography (not 
shown) confirms occult membrane without a classic component. Width of 
OCT B scan is equivalent to width of angiograms in (A), (D), and (E). (D) 
OCT angiogram of the outer retina. Small net seen in this image is due to 
elevation of part of the subretinal pigment epithelium membrane into the 
outer retina slab segmentation. (E) OCT angiogram of the deep capillary 
plexus appears normal.
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about 20% of the AMD eyes, there was absence or diminution 
of choroidal blood flow adjacent to the CNV.
Souied and colleagues28,29 have described OCTA features 
of type II and type III neovascularization in AMD. They 
described 2 morphologic patterns of type II CNV on 
SD-OCTA (RTVue XR Avanti Angiovue): a “medusa-
shaped” lesion and a “glomerulus-shaped” lesion. Most lesions 
were connected to a larger feeder vessel extending from the 
choroid. Eyes with type III CNV were characterized by a tuft-
shaped high-flow vascular network arising from the deep 
capillary plexus in the outer retinal layer with adjoining telan-
giectatic vessels.
Waheed and colleagues30 compared visualization of CNV 
using SD-OCTA (RTVue XR Avanti AngioVue) versus 
SS-OCTA (1050-nm prototype developed at Massachusetts 
Institute of Technology). Because SS-OCTA uses a longer 
1050-nm wavelength, it penetrates deeper into the choroid 
than 850-nm wavelength SD-OCTA. They imaged eyes with 
type I, type II, or combined type CNV in exudative AMD 
using both SD-OCTA and SS-OCTA. In almost all of the 
images, SS-OCTA detected a larger area of the CNV com-
pared with SD-OCTA. The mean CNV area visualized for 3 
mm × 3 mm images was 0.95 mm2 for SS-OCT and 0.34 mm2 
for SD-OCT. This may be due to the fact that SD-OCTA was 
unable to visualize occult parts of the neovascular complex. 
Given its longer wavelength, ultrahigh-speed SS-OCTA may 
be able to overcome signal attenuation associated with 
SD-OCTA such as from the RPE, media opacities, and any 
overlying hemorrhage.
Sarraf and colleagues31 have used OCTA to quantify the 
response of type II CNV lesions to anti-VEGF treatments in 
a patient with exudative AMD. They performed sequential 
SSADA OCTA of a type II neovascular membrane prior to 
and at various times following initiation of monthly ranibi-
zumab injections. They showed that the lesion area decreased 
by 40% at 4 weeks after the first injection and that the vascu-
lar density decreased by 50%. At 4 weeks after the second 
injection, the lesion size had further decreased by 30% and 
the vessel density had decreased by 25%. They noted that the 
caliber of the main feeder vessel did not change and hypoth-
esized that the larger feeder vessel may be more resistant to 
anti-VEGF therapy possibly due to the presence of overlying 
pericytes that do not surround the smaller vessel branches of 
the membrane.
Sarraf and colleagues32 have also studied type III CNV 
lesions with OCTA (RTVue XR Avanti AngioVue). In a study 
of 29 eyes with type III wet AMD, of which more than half 
had previously been treated with anti-VEGF, a distinct neovas-
cular membrane could be seen in 10 eyes (34%) on OCTA. In 
all of these eyes, the lesions were active on OCT with evidence 
of intraretinal or subretinal fluid. Type III CNV lesions 
appeared as small tufts of high-flow vessels in the outer retinal 
layer. In all eyes, a feeder vessel was seen connecting the CNV 
with the deep retinal capillary plexus. About 80% of lesions 
were associated with pigment epithelial detachment. In one 
patient who had follow-up imaging after receiving an intravit-
real aflibercept injection, the CNV lesion was no longer seen 
on subsequent OCTA.
Souied and colleagues33 used OCTA (RTVue XR Avanti 
AngioVue) to characterize the structural and vascular features 
of subretinal fibrosis. Subretinal fibrosis and atrophy develop 
following exudative AMD and is associated with a poor visual 
outcome. They analyzed 49 eyes in patients with evidence of 
subretinal fibrosis based on FA and SD-OCT. They identified 
several phenotypic morphologies of vascular networks found 
within subretinal fibrotic scars, which they have termed “pruned 
vascular tree,” “vascular loop,” and “tangled network.” These 
vascular networks could not be seen on FA and appeared only 
as a compact and homogeneous hyperreflective lesion on 
SD-OCT.
Figure 4. Type III choroidal neovascularization (CNV) in exudative 
age-related macular degeneration (retinal angiomatous proliferation) in 
the left eye of a 68-year-old man, treatment-naive. (A) 3 × 3 mm spectral 
domain optical coherence tomographic (SD-OCT) angiogram of the 
choriocapillaris showing patchy loss of flow signal due to overlying 
intraretinal fluid; (B) en face structural optical coherence tomography 
(OCT) of the same area showing patchy hyporeflectivity corresponding to 
intraretinal cystic fluid, as well as hyperreflectivity corresponding to 
retinal blood vessels; (C) OCT B scan through area of intraretinal fluid 
and type III CNV (arrow) (corresponding to the white dotted line in B). 
Width of OCT B scan is equivalent to width of angiograms in (A), (D), and 
(E). (D) OCT angiogram of the outer retina shows part of the CNV 
centrally. (E) OCT angiogram of the deep capillary plexus showing dilated 
CNV vessel with surrounding loss of flow signal due to intraretinal fluid.
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Conclusions
Optical coherence tomographic angiography is a new, rapid, 
noninvasive imaging modality that can provide detailed visuali-
zation of the retinal and choroidal vasculature with 3D depth 
resolution. Although the technology is still in its infancy, there 
is growing interest in using OCTA to image neovascularization 
for a multitude of diseases, including AMD. Optical coherence 
tomographic angiography can provide detailed visualization of 
the structure, size, location, and blood flow of neovascular mem-
branes. It may be useful in identifying nonexudative “subclinical 
CNV” lesions prior to detection with conventional imaging 
such as OCT and FA. Earlier detection could enable better 
monitoring of patients at high risk of conversion to neovascular 
AMD that may lead to earlier treatment, although the implica-
tions of earlier detection and treatment on visual prognosis 
remain to be seen. Although the benefits to OCTA are clear, 
there remain many limitations to this new imaging modality. 
Because it measures contrast based on movement, any back-
ground motion of the eye will cause noise artifact and degrade 
image quality. Media opacities and hemorrhage can cause 
shadow artifacts, and normal vasculature can lead to projection 
artifacts. Moreover, some neovascular membranes with low flow 
may not be visualized due to limits in the resolution of the 
machine. With time, more advanced algorithms and scanners 
will be able to more precisely subtract artifact and acquire 
images with ultrahigh resolution. Further studies are needed to 
correlate OCTA with clinical findings in both exudative and 
nonexudative AMD and to compare with other imaging 
modalities. Future investigations with OCTA to examine the 
natural history, progression, and response to treatment in AMD 
may ultimately lead to a better understanding of the pathogen-
esis of this disease and improved patient outcomes.
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